Literature DB >> 9794664

Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm.

L O Eckert1, S E Hawes, C E Stevens, L A Koutsky, D A Eschenbach, K K Holmes.   

Abstract

OBJECTIVE: To correlate symptoms, signs, and risk factors with positive wet mounts or cultures for Candida albicans and to develop an algorithm to diagnose vulvovaginal candidiasis.
METHODS: This cross-sectional study of 774 randomly selected women from an urban sexually transmitted disease (STD) clinic evaluated symptoms, signs, and risk factors associated with C albicans, detected by wet mount and culture, and constructed an algorithm.
RESULTS: C albicans, recovered from 186 (24%) of the 774 women, was associated with chief complaints of vulvar pruritus or burning. Elicited symptoms were vulvar pruritus, pain or burning, and external dysuria; signs were vulvar erythema, edema, fissures, vaginal erythema, and thick, curdy vaginal discharge. Among 545 women with symptoms of either increased vaginal discharge or vulvar pruritus or burning, only 155 (28%) had positive C albicans cultures, whereas bacterial vaginosis or other sexually transmitted infections were found in 288 (53%). In multivariate analysis, risk factors for positive C albicans culture included condom use, presentation after the 14th menstrual cycle day, sexual intercourse more than four times per month, recent antibiotic use, young age, past gonococcal infection, and absence of current gonorrhea or bacterial vaginosis. A clinical algorithm based on symptoms, signs, and selective use of wet mounts and cultures would have provided prompt treatment to 150 of 167 (90%) women with vulvovaginal candidiasis while minimizing the number of cultures performed.
CONCLUSION: A simple algorithm using symptoms, signs, wet mounts, and selective cultures can identify 90% of women with vulvovaginal candidiasis. In this STD clinic, vulvovaginal symptoms also require assessment for bacterial vaginosis, trichomoniasis, and cervical infection.

Entities:  

Mesh:

Year:  1998        PMID: 9794664     DOI: 10.1016/s0029-7844(98)00264-6

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  33 in total

1.  Vulvovaginal candidiasis.

Authors:  Jeanne Marrazzo
Journal:  BMJ       Date:  2003-05-10

2.  The development of evidence-based guidelines for over-the-counter treatment of vulvovaginal candidiasis.

Authors:  Christine M Bond; Margaret C Watson
Journal:  Pharm World Sci       Date:  2003-08

3.  Vulvovaginal candidiasis.

Authors:  D J White; A Vanthuyne
Journal:  Sex Transm Infect       Date:  2006-12       Impact factor: 3.519

4.  Patient preferences and treatment safety for uncomplicated vulvovaginal candidiasis in primary health care.

Authors:  Isabel Del-Cura González; Francisca García-de-Blas González; Teresa Sanz Cuesta; Jesús Martín Fernández; Justo M Del-Alamo Rodríguez; Rosa A Escriva Ferrairo; M Del Canto De-Hoyos Alonso; Laura Balsalobre Arenas; Ricardo Rodríguez Barrientos; Elisa Ceresuela Wiesmann; Cristina De-Alba Romero; Yolanda Ginés Díaz; Ana Pastor Rodríguez-Moñino; Blanca Gutiérrez Teira; Marta Sánchez-Celaya Del Pozo; Jesús Fernández Horcajuelo; María J Rojas Giraldo; Paulino Cubero González; Rocío A Vello Cuadrado; Beatriz López Uriarte; Jeannet Sánchez Yepes; Yolanda Hernando Sanz; M José Iglesias Piñeiro; Susana Tudanca Hernández; Fernando Gallardo Alonso; Ana I González González; Alicia Simón Fernández; Carmen Carballo; Ana Rey López; Fernanda Morales; Dolores Martínez López
Journal:  BMC Public Health       Date:  2011-01-31       Impact factor: 3.295

5.  Rapid detection of vaginal Candida species by newly developed immunochromatography.

Authors:  Hidehito Matsui; Hideaki Hanaki; Kengo Takahashi; Akihiko Yokoyama; Taiji Nakae; Keisuke Sunakawa; Satoshi Omura
Journal:  Clin Vaccine Immunol       Date:  2009-08-05

6.  Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013).

Authors:  W Mendling; K Friese; I Mylonas; E-R Weissenbacher; J Brasch; M Schaller; P Mayser; I Effendy; G Ginter-Hanselmayer; H Hof; O Cornely; M Ruhnke
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-04       Impact factor: 2.915

Review 7.  Candida infections of the genitourinary tract.

Authors:  Jacqueline M Achkar; Bettina C Fries
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

8.  Local expression of vaginal Th1 and Th2 cytokines in murine vaginal candidiasis under different immunity conditions.

Authors:  Shanjuan Chen; Shaohua Li; Yan Wu; Zhixiang Liu; Jiawen Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-08-15

9.  Prospective study of vaginal bacterial flora and other risk factors for vulvovaginal candidiasis.

Authors:  R Scott McClelland; Barbra A Richardson; Wisal M Hassan; Susan M Graham; James Kiarie; Jared M Baeten; Kishorchandra Mandaliya; Walter Jaoko; Jeckoniah O Ndinya-Achola; King K Holmes
Journal:  J Infect Dis       Date:  2009-06-15       Impact factor: 5.226

10.  The effect of itraconazole on the vaginal candidiasis under different immunity conditions in mice.

Authors:  Weixiang Ouyang; Shanjuan Chen; Shaohua Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.